Skip to main content
Loading...
Menu social network
LinkedIn
Facebook
X
Youtube
Menu top
Assistance
User account menu
Log in
Main navigation
Home
Programme
Download the app
App
Download the app
App
Menu
Login
Close
Main navigation mobile
Home
Programme
Menu top
Assistance
Menu social network
LinkedIn
Facebook
X
Youtube
25 results
D1.428 - Fungal Microbiome Diversity in Urban Forest Decreases Asthma and Allergic Inflammation
D1.431 - Associations of the composition of intestinal microbiota with the initial manifestations of IgE-mediated food allergy in children 6-12 months old
D1.433 - The effect of preventive administration of probiotic strain E. coli 083:H24:K31 on selected immune characteristics of eight-year-old children
- D3.239 - Trimethoprim-induced drug reaction with eosinophilia and systemic symptoms (DRESS) associated with reactivation of human herpesvirus-7 (HHV-7)
- D3.242 - Desensitization to ampicillin fixed drug eruption. Spotting the solution to fix the heart
- D3.243 - Successful subcutaneous desensitization protocols for Canakinumab, Trastuzumab, and Triptorelin: a case series report
- D3.244 - Diagnosing Drug-Induced Sweet Syndrome With Target-Like Lesions Amidst Malignancy And Infection
D3.245 - Positive HLA-B*13:01 Allele in a Patient with Clinical Diagnosis of Drug Induced Eosinophilia with Systemic Symptoms (DRESS)
- D3.246 - Symmetrical Drug-Related Intertriginous and Flexural Exanthema (SDRIFE) induced by enoxaparin: a case report and allergology work up
- D3.247 - A case report of multiple drug hypersensitivity triggered by DRESS to beta-lactamase inhibitors
- D3.248 - Anaphylactic shock after indocyanine green intracervical administration
- D3.249 - Delayed-Type Drug Allergy Combined with Adverse Drug Reactions
- D3.250 - Macrolide Hypersensitivity: Exploring the Value of Skin and Provocation Tests in a Portuguese Case Series
- D3.251 - Selective Facial Angioedema Induced by Propionic Acids: A Clinical Study of NSAID Idiosyncratic Reactions (Type 3a)
D3.419 - Prevalence of physical urticaria hives in patients with systemic mastocytosis and their relation to disease course – preliminary data
D3.411 - Targeting MRGPRX2 for the Treatment of Mast Cell-Driven Diseases
D3.412 - MRGPRX2 Specific Activation Signature is Enriched in Atopic Dermatitis Lesions and Wheals from Chronic Spontaneous Urticaria Compared to Adjacent Healthy Skin
D3.413 - Development of the Mastocytosis Symptom Severity Daily Diary (MS2D2) for Non-Advanced Systemic Mastocytosis (NonAdvSM) Patients and Establishing Content Validity
D3.414 - The Phase 2/3 Study of Elenestinib, a Highly Potent and Selective Tyrosine Kinase Inhibitor, in Patients With Indolent Systemic Mastocytosis
D3.415 - Clinical manifestations of Hereditary alpha-tryptasemia (HaT) in Patients with Mast Cell Activation Syndromes
Pagination
Current page
1
Page
2
Next page
Next
Last page
Last
Download the app
The congress at your fingertips
Available on
Download